Table 2. Association of tumor grade and tumor stage with anti-tcdB levels.
| Tumor grade | n=28 | Mean IgG | SD | p-value* | Mean IgA titer | SD | p-value* |
|---|---|---|---|---|---|---|---|
| Well-differentiated | 11 | 0.54 | 0.46 | 0.5337 | 0.21 | 0.23 | 0.7506 |
| Moderately differentiated | 14 | 0.63 | 0.64 | 0.19 | 0.22 | ||
| Poorly differentiated | 3 | 0.23 | 0.25 | 0.10 | 0.04 | ||
| Tumor stage | n=27 | Mean IgG | SD | p-value# | Mean IgA titer | SD | p-value# |
| Early stages (I/II) | 8 | 0.62 | 0.63 | 0.4845 | 0.22 | 0.27 | 0.2522 |
| Advanced stages (III/IV) | 19 | 0.46 | 0.48 | 0.13 | 0.11 | ||
SD: standard deviation. *One-way ANOVA. #Two-sample t-test with equal variances.
It should be noted that information was not available for the tumor stages and grades of 11 and 12 cases, respectively.